<DOC>
	<DOC>NCT01567085</DOC>
	<brief_summary>Primary Objective: To evaluate the safety and potential efficacy of eculizumab to prevent Antibody Mediated Rejection (AMR) in sensitized recipients of deceased donor kidney transplants.</brief_summary>
	<brief_title>Safety &amp; Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>1. Male or female patients â‰¥ 18 years old 2. Patients with Stage V chronic kidney disease who will receive a kidney transplant from a deceased donor to whom they are sensitized 3. History of prior exposure to HLA (Human Leukocyte Antigen): Prior solid organ or tissue allograft Pregnancy Blood transfusion Prior exposure to specific donor's HLA 1. Has received treatment with eculizumab at any time prior to enrolling in this study 2. ABO (A,B and O Blood GlycoproteinsBlood Type) incompatible with deceased donor 3. History of severe cardiac disease 4. Prior splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>